Manufacturer news from 09/23 News Brief

Roger Marchetti will join Amylin Pharmaceuticals as senior vice president, human resources and corporate services. Marchetti will take over for Martin Brown, who will be retiring from Amylin in October.

Amgen has appointed Phyllis Piano as vice president, corporate communications and philanthropy. Piano will be responsible for the company's strategic communications platform, including internal and external communications, public relations, communications issues management, master brand management, Web communications and Amgen's philanthropy efforts. Piano joins Amgen after serving as vice president, corporate affairs and communications at aerospace and defense company Raytheon.

Michael Gilman, executive vice president, research at Biogen Idec is leaving the company, effective Nov. 8. Alphonse Galdes, vice president, drug discovery and Rainer Fuchs, vice president, research informatics and operations, will assume Gilman's responsibilities on an interim basis.

Epix Pharmaceuticals, a developer of pharmaceuticals for magnetic resonance imaging (MRI), named Michael Astrue, former chief executive of Transkaryotic Therapies, as interim chief executive. In his new role, Astrue will help the company to execute its business plan in the imaging field and to define and pursue opportunities for growth beyond imaging. He will also assist the Board in its search for a permanent chief executive.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.